Impact of COVID-19 in allergen immunotherapy: An Italian survey

Main Article Content

Jaime Sánchez-López https://orcid.org/0000-0003-3600-8138
Enrico Heffler https://orcid.org/0000-0002-0492-5663
Giorgio Walter Canonica https://orcid.org/0000-0001-8467-2557

Keywords

allergen immunotherapy, COVID-19, subcutaneous immunotherapy, sublingual immunotherapy

Abstract

Allergen immunotherapy (AIT) is a common treatment for patients with allergic asthma and allergic rhinoconjunctivitis. There is evidence that the COVID-19 pandemic could have altered the administration of AIT in patients in some countries, as the pandemic caused major limitations to healthcare access and delivery. The objective of this study was to evaluate the impact of the disruption imposed by the pandemic on the perceptions and administration of AIT therapies in Italy. An online survey was carried out among Italian allergists between 22 February 2021 and 12 April 2021. The results show that Italian physicians (N=66) did not consider that the COVID-19 pandemic presented an added risk to patients with allergic asthma or rhinitis receiving AIT. Although most treatments continued, there were reduced rates of AIT therapy initiations and sublingual AIT was favored over subcutaneous AIT.

Abstract 377 | PDF Downloads 395 HTML Downloads 82 XML Downloads 15

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. 10.1056/NEJMoa2001017

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5

3. Hagemann J, Onorato GL, Jutel M, Akdis CA, Agache I, Zuberbier T, et al. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021;76(8):2354–66. 10.1111/all.14815

4. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558–62. 10.1016/s0091-6749(98)70271-4

5. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597–631. 10.1111/all.13201

6. Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017;72(12):1825–48. 10.1111/all.13208

7. Woehlk C, von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. Allergic asthma is associated with increased risk of infections requiring antibiotics. Ann Allergy Asthma Immunol. 2018; 120(2):169-176.e1. 10.1016/j.anai.2017.11.015

8. Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–8. 10.1016/j.jaci.2020.08.008

9. Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020;75(7): 1546–54. 10.1111/all.14336

10. Larenas-Linnemann DE, Epstein T, Ponda P, Bernstein D, Williams P, Creticos P. Gaps in allergen immunotherapy administration and subcutaneous allergen immunotherapy dose adjustment schedules: Need for prospective data. Ann Allergy Asthma Immunol. 2020;125(5):505–506.e2. 10.1016/j.anai.2020.07.015

11. Aytekin ES, Soyer Ö, Şekerel BE, Şahiner ÜM. Subcutaneous Allergen immunotherapy in children: Real life compliance and effect of COVID-19 pandemic on compliance. Int Arch Allergy Immunol. 2021;182(7):631–6. 10.1159/000514587

12. Pfaar O, Agache I, Bonini M, Brough HA, Chivato T, Del Giacco SR, et al. COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021;76(11):3504–16. 10.1111/all.14793

13. Ricci G, Pallotta G, Sirignano A, Amenta F, Nittari G. Consequences of COVID-19 outbreak in Italy: Medical responsibilities and governmental measures. Front Public Health. 2020;8:588852. 10.3389/fpubh.2020.588852

14. Malipiero G, Paoletti G, Puggioni F, Racca F, Ferri S, Marsala A, et al. An academic allergy unit during COVID-19 pandemic in Italy. J Allergy Clin Immunol. 2020;146(1):227. 10.1016/j.jaci.2020.04.003

15. Tanno LK, Demoly P, Martin B, Berstein J, Morais-Almeida M, Levin M, et al. Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic. World Allergy Organ J. 2021;14(2):100515. 10.1016/j.waojou.2021.100515

16. Rodriguez del Rio P, Caimmi D, Rico P, Vidal C, Carmen M, Pintoiu IM, et al. Real-life report of allergen immunotherapy management during the COVID-19 outbreak in France and Spain. Clin Exp Allergy. 2021:cea.14043. 10.1111/cea.14043